Acellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010–2015, a Canadian Immunization Research Network (CIRN) study

Simple item page
dc.contributor.authorBell, Christopher A.
dc.contributor.authorRussell, Margaret L.
dc.contributor.authorDrews, Steven J.
dc.contributor.authorSimmonds, Kimberley A.
dc.contributor.authorSvenson, Lawrence W.
dc.contributor.authorSchwartz, Kevin L.
dc.contributor.authorKwong, Jeffrey C.
dc.contributor.authorMahmud, Salaheddin M.
dc.contributor.authorCrowcroft, Natasha S.
dc.date.accessioned2019-06-03T16:41:45Z
dc.date.available2019-06-03T16:41:45Z
dc.date.issued2019-06-01
dc.description.abstractBackground Pertussis is still frequently reported in Canada. In Alberta, pertussis incidence ranged from 1.8 to 20.5 cases per 100,000 persons for 2004–2015. Most cases occurred in those aged <15 years. In Alberta, acellular formulations replaced whole-cell in 1997. We investigated pertussis vaccine effectiveness (VE) using a test-negative design (TND) study. Methods We included all persons who had a real-time PCR laboratory test for Bordetella pertussis between January 1, 2010 and August 31, 2015, in the province of Alberta, Canada. Vaccination history was obtained from Alberta’s immunization repository. Vaccination status was classified as complete, incomplete, or unvaccinated, based on the province’s vaccination schedule. Persons who had received ≥one dose of whole cell vaccine were excluded from analysis. Multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for pertussis infection by time since last vaccination. We adjusted for vaccination status, age, sex, neighbourhood income, urban/rural status, and the presence of a co-morbid condition. VE was calculated as [(1 − aOR) * 100]. Results Of the 12,149 tests available, 936 (7.7%) were positive for Bordetella pertussis. Among the full cohort, VE was 90% (95% CI 87–92%) at 1 year, 81% (95% CI 77–85%) at 1–3 years, 76% (95% CI 68–82%) at 4–7 years, and 37% (95% CI 11–56%) at 8 or more years since a last dose of acellular pertussis vaccine. Conclusions Pertussis VE was highest in the first year after vaccination, then declined noticeably as years since a last vaccination increased. Our results suggest that a large number of adolescents and adults are susceptible to infection with Bordetella pertussis. Regular boosters throughout childhood, adolescence, and during pregnancy may be needed.en_US
dc.description.grantingagencyCanadian Institutes of Health Research - Foundation Schemeen_US
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2019.05.067en_US
dc.identifier.urihttp://hdl.handle.net/1880/110464
dc.identifier.urihttps://doi.org/10.11575/PRISM/43836
dc.language.isoengen_US
dc.publisher.hasversionPost-printen_US
dc.publisher.institutionUniversity of Calgaryen_US
dc.publisher.institutionUniversity of Alberta Hospitalen_US
dc.publisher.institutionAlberta Health Servicesen_US
dc.publisher.institutionAlberta Ministry of Healthen_US
dc.publisher.institutionUniversity of Torontoen_US
dc.publisher.institutionPublic Health Ontarioen_US
dc.publisher.institutionUniversity of Manitobaen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.subjectAcellular pertussis vaccineen_US
dc.subjectWhooping coughen_US
dc.subjectVaccine effectivenessen_US
dc.subjectWaning immunityen_US
dc.subjectEpidemiologyen_US
dc.subjectCanadaen_US
dc.subjectICESen_US
dc.titleAcellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010–2015, a Canadian Immunization Research Network (CIRN) studyen_US
dc.typejournal articleen_US
Files
Original bundle
Now showing 1 - 5 of 6
Thumbnail Image
Name:
Postprint_Final.pdf
Size:
194.49 KB
Format:
Adobe Portable Document Format
Description:
main article
Download
Thumbnail Image
Name:
Figure 1_Final.pdf
Size:
172.2 KB
Format:
Adobe Portable Document Format
Description:
Figure 1
Download
Thumbnail Image
Name:
Figure 2_Final.pdf
Size:
63.48 KB
Format:
Adobe Portable Document Format
Description:
Figure 2
Download
Thumbnail Image
Name:
Figure 3_Final.pdf
Size:
156.64 KB
Format:
Adobe Portable Document Format
Description:
Figure 3
Download
Thumbnail Image
Name:
Table 1_Final.pdf
Size:
50.58 KB
Format:
Adobe Portable Document Format
Description:
Table 1
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.92 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Cumming School of Medicine Research & Publications